Comparative Pharmacology
Head-to-head clinical analysis: CLINDAMYCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus LINCOMYCIN HCL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINDAMYCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus LINCOMYCIN HCL.
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs LINCOMYCIN HCL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversibly binds to the 50S subunit of bacterial ribosomes, inhibiting peptide bond formation and protein synthesis. May also act as a bacterial protein synthesis inhibitor by dissociating ribosomes.
Lincomycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, inhibiting peptide bond formation and translocation.
Adult: 300-600 mg IV every 6-8 hours, up to 2.7 g/day in 3-4 divided doses for severe infections.
600 mg IM every 12-24 hours or 600 mg IV every 8-12 hours, up to 8 g/day for severe infections.
None Documented
None Documented
The terminal elimination half-life is approximately 2.4 hours in adults with normal renal function, but increases to 3-5 hours in patients with severe hepatic impairment. Renal impairment has minimal effect. In neonates, half-life may be prolonged (up to 8-12 hours).
4-5 hours (prolonged in renal impairment, up to 10 hours in anuria; no significant change in hepatic disease).
Clindamycin is primarily excreted via bile and feces (approximately 90% as metabolites), with renal elimination accounting for about 10% (parent drug and N-demethylated metabolite). Less than 1% is excreted unchanged in urine.
Renal (approximately 40% unchanged in urine) and biliary/fecal (approximately 50% as active drug and metabolites).
Category A/B
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic